China's medical products administrator accepted Jiangsu Hengrui Medicine (SHA:600276) subsidiary Suzhou Shengdia Biopharmaceutical's marketing application for trastuzumab injection, according to a Friday filing with the Shanghai Stock Exchange.
The injection is indicated for the treatment of human epidermal growth factor receptor 2-mutated non-small cell lung cancer, the filing said.
HER2 is a protein involved in normal cell growth, and some cancers tend to overproduce HER2.
Price (RMB): ¥44.77, Change: ¥-0.20, Percent Change: -0.44%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments